Recent Updates
Recently added Catalysts
ATNM

Letter of Intent

Monday, December 17, 2012 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Letter of Intent

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~21 mo
Low dilution risk
Lead asset
131I-apamistamab
Phase 3 · Acute Leukemia

Full Press Release Details

Letter of Intent.
ShareAdd on Google
Tags: ATNM Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 17, 2012

Biotech snapshot

Cash runway
$36M liquidity · $2M/mo burn
~21 mo
Low dilution risk
Lead asset
131I-apamistamabPhase 3
Acute Leukemia →